Academic literature on the topic 'Barbara B. Smith'

Rare Book Librarianship: An Introduction and Guide aims to provide a holistic view of the duties of the rare book librarian. The intended audience is students wishing to pursue rare book librarianship as a career as well as librarians (or archivists) who are new to the field. The authors acknowledge that many issues addressed in the book are applicable to the wider field of special collections, but argue that rare book librarianship is a specialization that requires specific attention. While this volume does contribute many words of wisdom specific to rare books, librarians or archivists already working in a special . . .

Background:Systemic lupus erythematosus (SLE) patients shown an increased risk of low bone mass as a result of multifactorial events: physical inactivity, persistent inflammation, low vitamin D levels (photosensitivity) and glucocorticoid treatment. Trabecular Bone Score (TBS), is an index extracted from the dual-energy X-ray absorptiometry (DXA) that provides an indirect measurement of bone axial microarchitecture and allows to get information about bone quality in several rheumatic diseases (1-4).Objectives:The aims of this study were to examine the prevalence and risk factors for low bone mineral density (BMD) (osteoporosis or osteopenia) in female patients affected by SLE and to compare with matched healthy subjects (CNT).Methods:70 female patients (mean age 41±20 years) affected by SLE and 65 age- matched CNT (mean age 46±7 years) were enrolled. Bone Mineral Density (BMD, g/cm2) of the lumbar spine (L1-L4) was analyzed using a DXA scan (GE, Lunar Prodigy). Lumbar spine TBS was derived for each spine DXA examination using the TBS index (TBS iNsight Medimaps).Results:The mean BMD±SD was 0.47±0.57 g/cm2 at the lumbar spine and 0.78 ± 0.22 g/cm2 at the hip in SLE patients. The prevalence of osteopenia was 40.0% and was 19.4% of osteoporosis in SLE patients. Most of SLE patients (75%) presented a bone loss that was significantly higher when compared with control group (p<0.001). Lumbar spine TBS score was found significantly lower in SLE patients compared with CNT (0.687±0.675 vs, 1.294±0.809 p<0.001, respectively) and of 0,47±0,94 times lower than expected from the concomitant reference BMD value.Conclusion:The study shows that the further TBS analysis, independently from the concomitant BMD value, is significatively lower then expected in SLE patients. The detection of the TBS, together with the BMD, may offer a more reliable indication of the real whole bone condition in chronic and systemic inflammatory rheumatic diseases, such as SLE.References:[1]Cutolo M et al. Ann Rheum Dis. 2009;68 446-7; 2 Dey M et al. Lupus. 018;271547-1551; 3 Ruaro B, Casabella A, et al. Rheumatology (Oxford). 2018;57:1548-1554. 4 Ruaro B, Casabella A, et al. Clin Rheumatol. 2018 Nov;37(11):3057-3062.Disclosure of Interests:Andrea Casabella: None declared, Sabrina Paolino: None declared, Elisa Alessandri: None declared, Vanessa Smith Grant/research support from: The affiliated company received grants from Research Foundation - Flanders (FWO), Belgian Fund for Scientific Research in Rheumatic diseases (FWRO), Boehringer Ingelheim Pharma GmbH & Co and Janssen-Cilag NV, Consultant of: Boehringer-Ingelheim Pharma GmbH & Co, Speakers bureau: Actelion Pharmaceuticals Ltd, Boehringer-Ingelheim Pharma GmbH & Co and UCB Biopharma Sprl, Barbara Ruaro: None declared, Carmen Pizzorni: None declared, Alberto Sulli Grant/research support from: Laboratori Baldacci, Maurizio Cutolo Grant/research support from: Bristol-Myers Squibb, Actelion, Celgene, Consultant of: Bristol-Myers Squibb, Speakers bureau: Sigma-Alpha

Background:Autoimmune diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), are associated with autoantibody production and dysregulated T- and B-cell responses. Rozibafusp alfa (AMG 570) is a first-in-class bispecific antibody-peptide conjugate targeting T- and B-cell activity through inhibition of ICOSL and BAFF and is currently in phase 2 clinical development for the treatment of SLE.Objectives:This interim analysis of a phase 1b study (NCT03156023) reports the safety, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of rozibafusp alfa in subjects with RA.Methods:Subjects (N~34; age 18–75 years) with active RA, defined as a disease activity score (DAS28-CRP) >2.6, were randomized 3:1 to receive rozibafusp alfa or placebo subcutaneously every 2 weeks for 10 weeks (6 doses), with 24 weeks of follow-up. Subjects were divided into 4 cohorts to study 4 ascending doses of rozibafusp alfa. All subjects were maintained on a stable dose of methotrexate. The primary endpoint was the subject incidence of treatment-emergent adverse events (TEAEs). Additional assessments included serum PK profiles, PD (eg, ICOSL receptor occupancy [RO], changes in peripheral blood B cells), incidence of anti-rozibafusp alfa antibodies, and Patient and Physician Global Assessments (PtGA and PhGA) of disease activity.Results:As of June 5, 2019, 34 subjects were enrolled and included in this interim analysis. Rozibafusp alfa was generally well tolerated. TEAEs occurred in 92.3% and 87.5% of subjects receiving rozibafusp alfa and placebo, respectively. Most of these events were of grade ≤2 severity. The most common TEAE was upper respiratory infection (23.1%) for subjects receiving rozibafusp alfa and nasopharyngitis (37.5%) for subjects receiving placebo. No treatment-related AEs were of grade ≥3 severity and occurred in >2 subjects. Rozibafusp alfa demonstrated a nonlinear PK profile with greater than a dose-proportional increase in concentration across evaluated doses. The terminal half-life of rozibafusp alfa ranged from 5 to 11 days, with longer half-lives at higher dose levels. ICOSL RO on circulating B-cells was dose-related and reversible; upon multiple dosing, >90% mean RO was observed in cohorts 3 and 4. Treatment with rozibafusp alfa reduced the percentage of naïve B-cells and increased the percentage of memory B-cells in all cohorts. As of March 22, 2019, 2 of 18 (11.1%) rozibafusp alfa-treated subjects developed anti-rozibafusp alfa antibodies with no correlation to safety or AEs. Preliminary analysis of disease-related activity showed a trend for greater numerical improvement from baseline in PtGA and PhGA with rozibafusp alfa vs. placebo in cohorts 3 and 4.Conclusion:This interim analysis is the first to report the safety and tolerability of multiple ascending doses of rozibafusp alfa in RA subjects, with preliminary efficacy findings observed in the highest dose cohorts. PK/PD analysis demonstrated nonlinear, target-mediated disposition consistent with cell surface target interaction and PD activity consistent with dual ICOSL/BAFF neutralization. These findings informed the design and dose selection of an ongoing phase 2, randomized, placebo-controlled study to assess the efficacy and safety of rozibafusp alfa in subjects with active SLE and inadequate responses to standard of care therapy.Acknowledgments:Amgen Inc. and AstraZeneca sponsored this phase 1b studyDisclosure of Interests:Lubna Abuqayyas Shareholder of: Stockholder of Amgen Inc., Employee of: Employee of Amgen Inc., Laurence Cheng Shareholder of: Stockholder of Amgen Inc., Employee of: Former employee of Amgen Inc., Deepali Mitragotri Shareholder of: Stockholder of Amgen Inc., Employee of: Employee of Amgen Inc., Shawna Smith Shareholder of: Stockholder of Amgen Inc., Employee of: Employee of Amgen Inc., Marcia Teixeira dos Santos Shareholder of: Stockholder of Amgen Inc., Employee of: Employee of Amgen Inc., Yanchen Zhou Shareholder of: Stockholder of Amgen Inc., Employee of: Employee of Amgen Inc., Vishala Chindalore Grant/research support from: Nektar Therapeutics for conducted studies, Speakers bureau: > 5 years ago, Stanley Cohen Grant/research support from: Grant and research support from Amgen, AbbVie, Pfizer, Genentech, and Lilly, Consultant of: Consultant for Amgen, AbbVie, Pfizer, Genentech and Lilly, Alan Kivitz Shareholder of: AbbVie, Amgen, Gilead, GSK, Pfizer Inc, Sanofi, Consultant of: AbbVie, Boehringer Ingelheim,,Flexion, Genzyme, Gilead, Janssen, Novartis, Pfizer Inc, Regeneron, Sanofi, SUN Pharma Advanced Research, UCB, Paid instructor for: Celgene, Genzyme, Horizon, Merck, Novartis, Pfizer, Regeneron, Sanofi, Speakers bureau: AbbVie, Celgene, Flexion, Genzyme, Horizon, Merck, Novartis, Pfizer Inc, Regeneron, Sanofi, Maximilian Posch: None declared, Barbara Sullivan Shareholder of: Shareholder of Amgen Inc., Employee of: Former employee of Amgen Inc. Current employee of Ultragenyx, Jane Parnes Shareholder of: Stockholder of Amgen Inc., Employee of: Employee of Amgen Inc.

A World Among these Islands: Essays on Literature, Race, and National Identity in Antillean America, by Roberto Márquez (reviewed by Peter Hulme) Caribbean Reasonings: The Thought of New World, The Quest for Decolonisation, edited by Brian Meeks & Norman Girvan (reviewed by Cary Fraser) Elusive Origins: The Enlightenment in the Modern Caribbean Historical Imagination, by Paul B. Miller (reviewed by Kerstin Oloff) Caribbean Perspectives on Modernity: Returning Medusa’s Gaze, by Maria Cristina Fumagalli (reviewed by Maureen Shay) Who Abolished Slavery: Slave Revolts and Abolitionism: A Debate with João Pedro Marques, edited by Seymour Drescher & Pieter C. Emmer, and Abolitionism and Imperialism in Britain, Africa, and the Atlantic, edited by Derek R . Peterson (reviewed by Claudius Fergus) The Mediterranean Apprenticeship of British Slavery, by Gustav Ungerer (reviewed by James Walvin) Children in Slavery through the Ages, edited by Gwyn Campbell, Suzanne Miers & Joseph C. Miller (reviewed by Indrani Chatterjee) The Invisible Hook: The Hidden Economics of Pirates, by Peter T. Leeson (reviewed by Kris Lane) Theorizing a Colonial Caribbean-Atlantic Imaginary: Sugar and Obeah, by Keith Sandiford (reviewed by Elaine Savory) Created in the West Indies: Caribbean Perspectives on V.S. Naipaul, edited by Jennifer Rahim & Barbara Lalla (reviewed by Supriya M. Nair) Thiefing Sugar: Eroticism between Women in Caribbean Literature, by Omise’eke Natasha Tinsley (reviewed by Lyndon K. Gill) Haiti Unbound: A Spiralist Challenge to the Postcolonial Canon, by Kaiama L. Glover (reviewed by Asselin Charles) Divergent Dictions: Contemporary Dominican Literature, by Néstor E. Rodríguez (reviewed by Dawn F. Stinchcomb) The Caribbean Short Story: Critical Perspectives, edited by Lucy Evans, Mark McWatt & Emma Smith (reviewed by Leah Rosenberg) Society of the Dead: Quita Manaquita and Palo Praise in Cuba, by Todd Ramón Ochoa (reviewed by Brian Brazeal) El Lector: A History of the Cigar Factory Reader, by Araceli Tinajero (reviewed by Juan José Baldrich) Blazing Cane: Sugar Communities, Class, and State Formation in Cuba, 1868-1959, by Gillian McGillivray (reviewed by Consuelo Naranjo Orovio) The Purposes of Paradise: U.S. Tourism and Empire in Cuba and Hawai’i, by Christine Skwiot (reviewed by Amalia L. Cabezas) A History of the Cuban Revolution, by Aviva Chomsky (reviewed by Michelle Chase) The Cubalogues: Beat Writers in Revolutionary Havana, by Todd F. Tietchen (reviewed by Stephen Fay) The Devil in the Details: Cuban Antislavery Narrative in the Postmodern Age, by Claudette M. Williams (reviewed by Gera Burton) Screening Cuba: Film Criticism as Political Performance during the Cold War, by Hector Amaya (reviewed by Ann Marie Stock) Perceptions of Cuba: Canadian and American Policies in Comparative Perspective, by Lana Wylie (reviewed by Julia Sagebien) Forging Diaspora: Afro-Cubans and African Americans in a World of Empire and Jim Crow, by Frank Andre Guridy (reviewed by Susan Greenbaum) The Irish in the Atlantic World, edited by David T. Gleeson (reviewed by Donald Harman Akenson) The Chinese in Latin America and the Caribbean, edited by Walton Look Lai & Tan Chee-Beng (reviewed by John Kuo Wei Tchen) The Island of One People: An Account of the History of the Jews of Jamaica, by Marilyn Delevante & Anthony Alberga (reviewed by Barry Stiefel) Creole Jews: Negotiating Community in Colonial Suriname, by Wieke Vink (reviewed by Aviva Ben-Ur) Only West Indians: Creole Nationalism in the British West Indies, by F.S.J. Ledgister (reviewed by Jerome Teelucksingh) Cultural DNA: Gender at the Root of Everyday Life in Rural Jamaica, by Diana J. Fox (reviewed by Jean Besson) Women in Grenadian History, 1783-1983, by Nicole Laurine Phillip (reviewed by Bernard Moitt) British-Controlled Trinidad and Venezuela: A History of Economic Interests and Subversions, 1830-1962, by Kelvin Singh (reviewed by Stephen G. Rabe) Export/Import Trends and Economic Development in Trinidad, 1919-1939, by Doddridge H.N. Alleyne (reviewed by Rita Pemberton) Post-Colonial Trinidad: An Ethnographic Journal, by Colin Clarke & Gillian Clarke (reviewed by Patricia van Leeuwaarde Moonsammy) Poverty in Haiti: Essays on Underdevelopment and Post Disaster Prospects, by Mats Lundahl (reviewed by Robert Fatton Jr.) From Douglass to Duvalier: U.S. African Americans, Haiti, and Pan Americanism, 1870-1964, by Millery Polyné (reviewed by Brenda Gayle Plummer) Haiti Rising: Haitian History, Culture and the Earthquake of 2010, edited by Martin Munro (reviewed by Jonna Knappenberger) Faith Makes Us Live: Surviving and Thriving in the Haitian Diaspora, by Margarita A. Mooney (reviewed by Rose-Marie Chierici) This Spot of Ground: Spiritual Baptists in Toronto, by Carol B. Duncan (reviewed by James Houk) Interroger les morts: Essai sur le dynamique politique des Noirs marrons ndjuka du Surinam et de la Guyane, by Jean-Yves Parris (reviewed by H.U.E. Thoden van Velzen & W. van Wetering)

-Jay B. Haviser, Jerald T. Milanich ,First encounters: Spanish explorations in the Caribbean and the United States, 1492-1570. Gainesville FL: Florida Museum of Natural History & University Presses of Florida, 1989. 221 pp., Susan Milbrath (eds)-Marvin Lunenfeld, The Libro de las profecías of Christopher Columbus: an en face edition. Delano C. West & August Kling, translation and commentary. Gainesville FL: University of Florida Press, 1991. x + 274 pp.-Suzannah England, Charles R. Ewen, From Spaniard to Creole: the archaeology of cultural formation at Puerto Real, Haiti. Tuscaloosa AL; University of Alabama Press, 1991. xvi + 155 pp.-Piero Gleijeses, Bruce Palmer Jr., Intervention in the Caribbean: the Dominican crisis of 1965. Lexington KY: University Press of Kentucky, 1989.-Piero Gleijeses, Herbert G. Schoonmaker, Military crisis management: U.S. intervention in the Dominican Republic, 1965. Westport CT: Greenwood Press, 1990. 152 pp.-Jacqueline A. Braveboy-Wagner, Fitzroy André Baptiste, War, cooperation, and conflict: the European possessions in the Caribbean, 1939-1945. Westport CT: Greenwood Press, 1988. xiv + 351 pp.-Peter Meel, Paul Sutton, Europe and the Caribbean. London: Macmillan Caribbean, 1991. xii + 260 pp.-Peter Meel, Betty Secoc-Dahlberg, The Dutch Caribbean: prospects for democracy. New York: Gordon and Breach, 1990. xix + 333 pp.-Michiel Baud, Rosario Espinal, Autoritarismo y democracía en la política dominicana. San José, Costa Rica: Ediciones CAPEL, 1987. 208 pp.-A.J.G. Reinders, J.M.R. Schrils, Een democratie in gevaar: een verslag van de situatie op Curacao tot 1987. Assen, Maastricht: Van Gorcum, 1990. xii + 292 pp.-Andrés Serbin, David W. Dent, Handbook of political science research on Latin America: trends from the 1960s to the 1990s. Westport CT: Greenwood, 1990.-D. Gail Saunders, Dean W. Collinwood, The Bahamas between worlds. Decatur IL: White Sound Press, 1989. vii + 119 pp.-D. Gail Saunders, Dean W. Collinwood ,Modern Bahamian society. Parkersburg IA: Caribbean Books, 1989. 278 pp., Steve Dodge (eds)-Peter Hulme, Pierrette Frickey, Critical perspectives on Jean Rhys. Washington DC: Three Continents Press, 1990. 235 pp.-Alvina Ruprecht, Lloyd W. Brown, El Dorado and Paradise: Canada and the Caribbean in Austin Clarke's fiction. Parkersburg IA: Caribbean Books, 1989. xv + 207 pp.-Ineke Phaf, Michiel van Kempen, De Surinaamse literatuur 1970-1985: een documentatie. Paramaribo: Uitgeverij de Volksboekwinkel, 1987. 406 pp.-Genevieve Escure, Barbara Lalla ,Language in exile: three hundred years of Jamaican Creole. Tuscaloosa AL: University of Alabama Press, 1990. xvii + 253 pp., Jean D'Costa (eds)-Charles V. Carnegie, G. Llewellyn Watson, Jamaican sayings: with notes on folklore, aesthetics, and social control.Tallahassee FL: Florida A & M University Press, 1991. xvi + 292 pp.-Donald R. Hill, Kaiso, calypso music. David Rudder in conversation with John La Rose. London: New Beacon Books, 1990. 33 pp.-Mark Sebba, John Victor Singler, Pidgin and creole tense-mood-aspect systems. Amsterdam and Philadelphia: John Benjamins, 1990. xvi + 240 pp.-Dale Tomich, Pedro San Miguel, El mundo que creó el azúcar: las haciendas en Vega Baja, 1800-873. Río Piedras, Puerto Rico: Ediciones Huracán, 1989. 224 pp.-César J. Ayala, Juan José Baldrich, Sembraron la no siembra: los cosecheros de tabaco puertorriqueños frente a las corporaciones tabacaleras, 1920-1934. Río Piedras, Puerto Rico: Ediciones Huracán, 1988.-Robert Forster, Jean-Michel Deveau, La traite rochelaise. Paris: Kathala, 1990. 334 pp.-Ernst van den Boogaart, Johannes Menne Postma, The Dutch in the Atlantic slave trade, 1600-1815. Cambridge: Cambridge University Press, 1990. xiv + 428 pp.-W.E. Renkema, T. van der Lee, Plantages op Curacao en hun eigenaren (1708-1845): namen en data voornamelijk ontleend aan transportakten. Leiden, the Netherlands: Grafaria, 1989. xii + 87 pp.-Mavis C. Campbell, Wim Hoogbergen, The Boni Maroon wars in Suriname. Leiden, the Netherlands: E.J. Brill, 1990. xvii + 254 pp.-Rafael Duharte Jiménez, Carlos Esteban Dieve, Los guerrilleros negros: esclavos fugitivos y cimarrones en Santo Domingo. Santo Domingo: Fundación Cultural Dominicana, 1989. 307 pp.-Rosemarijn Hoefte, Hans Ramsoedh, Suriname 1933-1944: koloniale politiek en beleid onder Gouverneur Kielstra. Delft, the Netherlands: Eburon, 1990. 255 pp.-Gert Oostindie, Kees Lagerberg, Onvoltooid verleden: de dekolonisatie van Suriname en de Nederlandse Antillen. Tilburg, the Netherlands: Instituut voor Ontwikkelingsvraagstukken, Katholieke Universiteit Brabant, 1989. ii + 265 pp.-Aisha Khan, Anthony de Verteuil, Eight East Indian immigrants. Port of Spain: Paria, 1989. xiv + 318 pp.-John Stiles, Willie L. Baber, The economizing strategy: an application and critique. New York: Peter Lang, 1988. xiii + 232 pp.-Faye V. Harrison, M.G. Smith, Poverty in Jamaica. Kingston: Institute of social and economic research, 1989. xxii + 167 pp.-Sidney W. Mintz, Dorian Powell ,Street foods of Kingston. Mona, Jamaica: Institute of social and economic research, 1990. xii + 125 pp., Erna Brodber, Eleanor Wint (eds)-Yona Jérome, Michel S. Laguerre, Urban poverty in the Caribbean: French Martinique as a social laboratory. New York: St. Martin's Press, 1990. xiv + 181 pp.

Background: Ibrutinib, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) is approved for use in a variety of lymphomas. Priced at $130,000/year, Ibrutinib imposes a significant financial burden on patients and society[1]. The study serving as the basis for the currently approved dose [2] demonstrated &gt;95% BTK receptor occupancy at a dose of 2.5 mg/kg. Data suggests that lower doses of Ibrutinib are equally effective[3] and dose reductions[4, 5] do not compromise outcome. Objective: To evaluate patient outcomes and cost savings with clinically indicated low dose (LD) of Ibrutinib in a community practice in hematological malignancies. Method: All patients treated with standard and LD Ibrutinib between January 2014 and July 2020 were identified. Reason for dose modification and best responses were abstracted. Patients with inadequate follow up or less than a week of treatment were excluded from the analysis. Responses were defined based on the iwCLL response criteria for Chronic Lymphocytic Leukemia (CLL), Lugano criteria for Non-Hodgkin's Lymphoma and International Working Group on Waldenström's Macroglobulinemia (WM), as applicable. To calculate drug cost at lower doses of Ibrutinib, cumulative number of patient-months on different dose levels of ibrutinib was calculated by adding the number of months each patient had remained at the dose level at the time of data cut-off. Drug cost at LD was calculated by multiplying monthly wholesale acquisition price for different dose levels of ibrutinib by the cumulative number of patient-months at that dose level. Cost differential between actual drug cost and projected drug cost at full dose was calculated. Results: 98 patients were identified. 10 were excluded from the analysis based on drug not started (3), inadequate follow-up (3), other (4). Median length of follow up for all patients was 20 months (4-70 months) and on LD Ibrutinib 12.5 months (1-60 months). 10 and 12 patients received 140 mg and 280 mg of Ibrutinib respectively due to side effects. 61 patients had CLL, 9 WM, 15 mantle cell lymphoma (MCL), and 2 marginal zone lymphoma (MZL). Response rates were similar across diagnoses and dose levels (TABLE 1 and FIGURE 1). Progressive disease (PD) at low dose was seen in 2 CLL patients with complex cytogenetics, deletion 17p and extensive prior therapy. The one WM patient with PD had been extensively pretreated. Cumulative patient-months at the 140 mg and 280 mg dose levels of Ibrutinib was 177 and 123 months respectively. Drug cost for the 140 mg and 280 mg Ibrutinib cohorts were $712,276 and $989,943 respectively, for a total cost of $1,702,219. Potential drug cost for the 420 or 560 mg dose of Ibrutinib for the same duration of therapy was $3,621,828. Cumulative cost avoidance on LD Ibrutinib was $1,919, 608. Conclusions: Clinically indicated low dose Ibrutinib was equally effective and produced significant cost savings. References: 1. Qiushi Chen, N.J., Turgay Ayer, William G. Wierda, Christopher R. Flowers, Susan M. O'Brien, Michael J. Keating, Hagop M. Kantarjian, and Jagpreet Chhatwal, Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. Journal of Clinical Oncology, 2017: p. 166-174. 2. Ranjana H. Advani, J.J.B., Jeff P. Sharman , Sonali M. Smith , Thomas E. Boyd , Barbara GrantKathryn S. Kolibaba , Richard R. Furman , Sara Rodriguez , Betty Y. Chang , Juthamas Sukbuntherng , Raquel Izumi , Ahmed Hamdy , Eric Hedrick , Nathan, Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies. Journal of Clinical Oncology, 2013: p. 88-94. 3. Lisa S. Chen, P.B., Nichole D. Cruz , Yongying Jiang , Qi Wu , Philip A. Thompson , Shuju Feng , Michael H. Kroll , Wei Qiao , Xuelin Huang , Nitin Jain , William G. Wierda , Michael J. Keating , Varsha Gandhi, A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood, 2018: p. 2249-2259. 4. Lad DP, Malhotra P, Khadwal A, Prakash G, Jain A, Varma S. Reduced Dose Ibrutinib Due to Financial Toxicity in CLL. Indian Journal of Hematology and Blood Transfusion, 2018. 35(2): p. 260-264. 5. Othman S. Akhtar, K.A., Ian Lund, Ryan Hare, Francisco J. Hernandez-Ilizaliturri & Pallawi Torka, Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL). Leukemia & Lymphoma, 2019. 60(7): p. 1650-1655. Disclosures No relevant conflicts of interest to declare. OffLabel Disclosure: Ibrutinib is approved at a dose of 420 mg orally daily or 560 mg orally daily in different lymphoproliferative disorders.

This thesis explores the relationship between ideology generated by advocates of the Women's Liberation Movement and President Kimball's purposes of using Relief Society to strengthen Latter-day Saint (LDS) women. Navigating women through the societal attack on womanhood, President Kimball, and other general Church leaders during his administration (1973-1985), taught LDS women of their privilege and duty to the organization and the importance of generating strength through a sisterhood focused on service. Relief Society programs, procedures, and curriculum were evaluated, adjusted, and reinforced to deepen women's commitment to divinely established roles, to enhance women's doctrinal confidence, and expand the influence of women's leadership. The purpose of this thesis is to show how Relief Society strengthened LDS women's commitment to family and influenced increased cooperative efforts in defending families through Relief Society and priesthood organizations.